Lumida
/ALT
⌘K
Altimmune Inc

Altimmune Inc

ALT
$3.27USD-0.61%-0.02 today

MARKET CAP

636.1M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$3
$6

AI Summary

Stalk
TrimMedium

In the Stage 4 decline, ALT remains in a lower-high/lower-low sequence below all major EMAs. Price action is sideways and indecisive around the 9/21 EMA band with RSI neutral. Medium-term structure is bearish while the long-term trend stays up. Execution calls for trimming into rallies up to the EMA resistance zone.

  • $519M cash covers expenses through 2027 and 2029 pemvidutide readouts, reducing near-term financing risk.
  • Phase 2 pemvidutide trials for AUD and MASH show significant efficacy trends, opening multi-indication potential.
  • Zero revenues last quarter underscore reliance on equity raises and potential dilution.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$4.4M$-68,000$426,000$20,000$41,000
YoY %-46.1%-101.5%+726.5%-95.3%+105.0%
P / Sales85.7x-10786.2x1314.9x25596.7x7757.5x
EV / Sales47.1x-9470.5x1036.6x24540.3x8032.5x
Gross Profit, Adj.$4.4M$-68,000$426,000$20,000$41,000
YoY %-46.1%-101.5%+726.5%-95.3%+105.0%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit47.1x-9470.5x1036.6x24540.3x8032.5x
EBITDA, Adj.$-85.0M$-87.2M$-83.0M$-102.9M$-94.4M
YoY %-56.3%-2.7%+4.8%-24.0%+8.3%
Margin %-1927.3%128304.4%-19491.3%-514670.0%-230187.8%
EV / EBITDA-2.4x-7.4x-5.3x-4.8x-3.5x
EBIT$-96.9M$-87.7M$-95.9M$-103.2M$-94.5M
YoY %-76.9%+9.5%-9.3%-7.6%+8.4%
Margin %-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
EV / EBIT-2.1x-7.3x-4.6x-4.8x-3.5x
Net Income$-97.1M$-84.7M$-88.4M$-95.1M$-88.1M
YoY %-98.0%+12.7%-4.4%-7.5%+7.3%
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (GAAP)-$2.35-$1.81-$1.66-$1.34-$1.00
YoY %-23.0%+23.0%+8.3%+19.3%+25.4%